A new approach to idiopathic pulmonary fibrosis
Keywords:
Idiopathic Pulmonary Fibrosis, Usual Interstitial Pneumonia, AntifibroticAbstract
In the last 22 years, idiopathic pulmonary fibrosis has undergone a revolutionary change, with publications of five international guidelines that ranged from diagnosis to treatment with drugs that act exclusively on fibrosis. A disease that establishes a life prognosis of up to 3.5 years, on average, has been uncovered and standards have been established in chest computed tomography and pulmonary pathology for diagnosis, in discussion with multidisciplinary teams. Treatment is another turning point in the knowledge of disease mechanism, with the recognition of fibrosis without prior inflammation and related to senility. This article presents a set of information and brings a new scenario in therapeutic management.
References
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496-504.
Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med. 2018;7(8):201.
Rabeyrin M, Thivolet F, Ferretti GR, Chalabreysse L, Jankowski A, Cottin V, et al. Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations. Ann Diagn Pathol. 2015;19(4):269-76.
Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One. 2012;7(3):e32921.
Crossno PF, Polosukhin VV, Blackwell TS, Johnson JE, Markin C, Moore PE, et al. Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Chest. 2010;137(4):969-73.
Bonella F, Campo I, Zorzetto M, Boerner E, Ohshimo S, Theegarten D, Taube C, Costabel U. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. Orphanet J Rare Dis. 2021;16(1):111.
Stock CJW, Renzoni EA. Telomeres in Interstitial Lung Disease. J Clin Med. 2021;10(7): 1384.
Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138-153.
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47.
Pacurari M, Mitra A, Turner T. Idiopathic Pulmonary Comorbidities and Mechanisms. Int J Inflam. 2021;2021:3963659.
Abuserewa ST, Duff R, Becker G. Treatment of Idiopathic Pulmonary Fibrosis. Cureus. 2021;13(5):e15360.
Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7(6):487-496.
